Importantly, many oncogenic drivers and their downstream mediators, such as proliferation-associated transcription factors, are positive regulators of BRCA1 and BRCA2. Activation of BRCA1 and BRCA2 by oncogenes offers the opportunity to selectively sensitize cancer cells to platinum by targeting defined genetic alterations that are not present in normal cells. Here, BRCA2 is linked to cancer.